{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:02:39Z","timestamp":1793826159489,"version":"4.6.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vaccine.2024.126483","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:02:12Z","timestamp":1730300532000},"page":"126483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Chikungunya vaccine development, challenges, and pathway toward public health impact"],"prefix":"10.1016","volume":"42","author":[{"given":"Clara","family":"Maure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanat","family":"Khazhidinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyolim","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Auzenbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Moyersoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Mendes Lima","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libia Milena Hernandez","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Anh","family":"Wartel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126483_bb0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0035-9203(55)90081-X","article-title":"An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952\u20131953 II. General description and epidemiology","volume":"49","author":"Lumsden","year":"1955","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.126483_bb0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0035-9203(55)90080-8","article-title":"An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952-53. I. Clinical features","volume":"49","author":"Robinson","year":"1955","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.126483_bb0020","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/S2214-109X(23)00046-3","article-title":"Aedes albopictus invasion across Africa: the time is now for cross-country collaboration and control","volume":"11","author":"Longbottom","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.126483_bb0025","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08347","article-title":"The global distribution of the arbovirus vectors Aedes aegypti and ae. Albopictus","volume":"4","author":"Kraemer","year":"2015","journal-title":"ELife"},{"key":"10.1016\/j.vaccine.2024.126483_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030263","article-title":"Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak","volume":"3","author":"Schuffenecker","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2024.126483_bb0035","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jmedent\/42.5.844","article-title":"Blood feeding patterns of Aedes aegypti and Aedes albopictus in Thailand","volume":"42","author":"Ponlawat","year":"2005","journal-title":"J Med Entomol"},{"key":"10.1016\/j.vaccine.2024.126483_bb0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11908-011-0180-1","article-title":"Chikungunya virus infection","volume":"13","author":"Simon","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2024.126483_bb0045","first-page":"11","article-title":"The clinical features, pathogenesis and methotrexate therapy of chronic chikungunya arthritis","author":"Amaral","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.126483_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009055","article-title":"Measuring the global burden of chikungunya and Zika viruses: a systematic review","volume":"15","author":"Puntasecca","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0055","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.idc.2019.08.006","article-title":"Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention","volume":"33","author":"Vairo","year":"2019","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.vaccine.2024.126483_bb0060","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1473-3099(23)00739-9","article-title":"Risk of death following chikungunya virus disease in the 100 million Brazilian cohort, 2015-18: a matched cohort study and self-controlled case series","volume":"24","author":"Cerqueira-Silva","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0065","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","article-title":"Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study","volume":"24","author":"Kang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207406","article-title":"Atypical and severe manifestations of chikungunya virus infection in French Guiana: a hospital-based study","volume":"13","author":"Bonifay","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.126483_bb0080","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4269\/ajtmh.2007.76.1189","article-title":"Seroprevalence of chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005","volume":"76","author":"Sergon","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.126483_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003994","article-title":"Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: a cohort study","volume":"19","author":"Nyamwaya","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2024.126483_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006919","article-title":"Chikungunya as a paradigm for emerging viral diseases: evaluating disease impact and hurdles to vaccine development","volume":"13","author":"Rezza","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0095","series-title":"The cost and burden of chikungunya in the Americas (public health theses - Yale University)","author":"Bloch","year":"2016"},{"key":"10.1016\/j.vaccine.2024.126483_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007563","article-title":"Estimating the cost of illness and burden of disease associated with the 2014-2015 chikungunya outbreak in the U.S. Virgin Islands","volume":"13","author":"Feldstein","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0105","article-title":"Molecular characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases","volume":"9","author":"Sahadeo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0115","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.01603-09","article-title":"Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates","volume":"84","author":"Volk","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126483_bb0120","first-page":"471","article-title":"Re-emergence of chikungunya and O\u2019nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships","volume":"81","author":"Powers","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2024.126483_bb0125","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/erv.12.84","article-title":"Chikungunya virus and prospects for a vaccine","volume":"11","author":"Weaver","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126483_bb0135","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation) Ixchiq chikungunya vaccine (live) 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ixchiq (accessed June 4, 2024)."},{"key":"10.1016\/j.vaccine.2024.126483_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618807580","article-title":"The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines","volume":"26","author":"Franco","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.vaccine.2024.126483_bb0145","series-title":"Evaluation of broad-spectrum antiviral compounds against chikungunya infection using a phenotypic screening strategy [version 1; peer review: 2 approved with reservations, 1 not approved]. F1000Res","first-page":"1730","volume":"7","author":"Bonotto","year":"2018"},{"key":"10.1016\/j.vaccine.2024.126483_bb0150","first-page":"11","article-title":"Chikungunya virus: priority pathogen or passing trend?","author":"Montalvo Zurbia-Flores","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126483_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00357-8","article-title":"Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study","author":"McMahon","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0160","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2019.1574149","article-title":"51 years in of chikungunya clinical vaccine development: a historical perspective","volume":"15","author":"Reyes-Sandoval","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126483_bb0165","first-page":"14","article-title":"A review on chikungunya virus epidemiology, pathogenesis and current vaccine development","author":"de Lima Cavalcanti","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.126483_bb0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41541-023-00722-x","article-title":"Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need","volume":"8","author":"Cherian","year":"2023","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.126483_bb0195","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0200","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126483_bb0205","unstructured":"Valneva. Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate - Valneva 2022. https:\/\/valneva.com\/press-release\/valneva-successfully-completes-pivotal-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate\/ (accessed September 19, 2023)."},{"key":"10.1016\/j.vaccine.2024.126483_bb0230","author":"Hatchett"},{"key":"10.1016\/j.vaccine.2024.126483_bb0235","author":"Bharat Biotech International Limited"},{"key":"10.1016\/j.vaccine.2024.126483_bb0255","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1093\/infdis\/jiw369","article-title":"Chikungunya virus vaccines: viral vector-based approaches","volume":"214","author":"Ramsauer","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0260","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0265","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126483_bb0270","unstructured":"Themis Bioscience GmbH. Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202) 2021. https:\/\/clinicaltrials.gov\/study\/NCT02861586 (accessed May 27, 2024)."},{"key":"10.1016\/j.vaccine.2024.126483_bb0275","first-page":"8","article-title":"A single and un-Adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against chikungunya virus fully protects mice from lethal disease","author":"Campos","year":"2019","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2024.126483_bb0285","first-page":"11","article-title":"Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against chikungunya virus","author":"L\u00f3pez-Camacho","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.126483_bb0290","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126483_bb0295","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1016\/j.vaccine.2022.08.007","article-title":"Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: case characteristics and associations","volume":"40","author":"Laffan","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0300","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1016\/j.vaccine.2022.06.008","article-title":"Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: standardized template with key considerations for a risk\/benefit assessment","volume":"40","author":"Folegatti","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade8273","article-title":"A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans","volume":"15","author":"Raju","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.126483_bb0310","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0315","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.126483_bb0320","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.vaccine.2024.126483_bb0330","author":"Nordic"},{"key":"10.1016\/j.vaccine.2024.126483_bb0335","author":"Nordic"},{"key":"10.1016\/j.vaccine.2024.126483_bb0340","author":"Nordic"},{"key":"10.1016\/j.vaccine.2024.126483_bb0345","author":"Nordic"},{"key":"10.1016\/j.vaccine.2024.126483_bb0350","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1016\/j.vaccine.2023.04.064","article-title":"A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults","volume":"41","author":"Shaw","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-023-00429-2","volume":"9","author":"Bartholomeeusen","year":"2023","journal-title":"Chikungunya fever Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2024.126483_bb0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijid.2018.11.058","article-title":"Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial","volume":"79","author":"Shaw","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0365","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1038\/s41598-024-61922-6","article-title":"Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh","volume":"14","author":"Haq","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.126483_bb0370","first-page":"7","article-title":"Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera","author":"Roques","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2024.126483_bb0375","unstructured":"European Medicines Agency. European Medicines Agency decision P\/0159\/2021 2021. https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p\/0159\/2021-ema-decision-16-april-2021-agreement-paediatric-investigation-plan-granting-deferral\/aluminum-hydroxide-emea-002656-pip01-19_en.pdf (accessed May 27, 2024)."},{"key":"10.1016\/j.vaccine.2024.126483_bb0380","author":"Butantan Institute"},{"key":"10.1016\/j.vaccine.2024.126483_bb0390","author":"WHO\/BS\/2022.2434"},{"key":"10.1016\/j.vaccine.2024.126483_bb0405","first-page":"25","article-title":"How the research-based industry approaches vaccine development and establishes priorities","volume":"110","author":"Andr\u00e9","year":"2002","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2024.126483_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012075","article-title":"Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysis","volume":"18","author":"Auzenbergs","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0415","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-023-02929-0","article-title":"The full value of vaccine assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making","volume":"21","author":"Hutubessy","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2024.126483_bb0420","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.vaccine.2021.02.059","article-title":"National decision-making for the introduction of new vaccines: a systematic review, 2010-2020","volume":"39","author":"Donadel","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0425","article-title":"Vaccine value profile for chikungunya","author":"Flandes","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0430","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jval.2021.04.1273","article-title":"The CAPACITI decision-support tool for National Immunization Programs","volume":"24","author":"Botwright","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.126483_bb0435","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/21645515.2016.1259045","article-title":"Dengue vaccine acceptance and willingness to pay","volume":"13","author":"Harapan","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126483_bb0440","unstructured":"International Vaccine Institute. IVI and Gorgas Institute advocate for chikungunya vaccines at global meeting in Panama 2023. https:\/\/www.ivi.int\/ivi-and-gorgas-institute-advocate-for-chikungunya-vaccines-at-global-meeting-in-panama\/ (accessed June 4, 2024)."},{"key":"10.1016\/j.vaccine.2024.126483_bb0445","article-title":"CEPI launches call for proposals to develop vaccines against Rift Valley fever and Chikungunya viruses","author":"CEPI","year":"2019","journal-title":"CEPI"},{"key":"10.1016\/j.vaccine.2024.126483_bb0450","article-title":"The vaccine alliance","author":"Gavi","year":"2024","journal-title":"Eligibility"},{"key":"10.1016\/j.vaccine.2024.126483_bb0455","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/14760584.2016.1134329","article-title":"Financing dengue vaccine introduction in the Americas: challenges and opportunities","volume":"15","author":"Constenla","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126483_bb0460","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2023.50","volume":"47","author":"Cornejo","year":"2023","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.vaccine.2024.126483_bb0465","first-page":"11","article-title":"The future of epidemic and pandemic vaccines to serve global public health needs","author":"Farlow","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126483_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00097-1","article-title":"Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?","volume":"5","author":"Baylis","year":"2024","journal-title":"Lancet Microbe"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2024.126483_bb0475","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2019.08.086","article-title":"Oral cholera vaccine working Group of the Global Task Force on cholera control. Global oral cholera vaccine use, 2013-2018","volume":"38","author":"Pezzoli","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0480","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1016\/j.vaccine.2017.08.001","volume":"35","author":"Meiring","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0485","doi-asserted-by":"crossref","first-page":"S781","DOI":"10.1093\/infdis\/jiab449","article-title":"Typhoid conjugate vaccines: advancing the research and public health agendas","volume":"224","author":"Birkhold","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126483_bb0490","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/1468-0009.12503","article-title":"International collaboration to ensure equitable access to vaccines for COVID-19: the ACT-accelerator and the COVAX facility","volume":"99","author":"Eccleston-Turner","year":"2021","journal-title":"Milbank Q"},{"key":"10.1016\/j.vaccine.2024.126483_bb0495","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2021.08.101","article-title":"Collaboration in times of crisis: a study on COVID-19 vaccine R&D partnerships","volume":"39","author":"Druedahl","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126483_bb0500","first-page":"6","article-title":"SARS-CoV-2 vaccines: a triumph of science and collaboration","author":"Golob","year":"2021","journal-title":"JCI Insight"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:44:36Z","timestamp":1741873476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24011654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":80,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0264410X24011654"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126483","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chikungunya vaccine development, challenges, and pathway toward public health impact","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126483"}}